Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Actinium Pharmaceuticals Inc (NY: ATNM )

7.380 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 7.380
Bid (Size) 7.400 (5)
Ask (Size) 9.450 (1)
Prev. Close 7.380
Today's Range 7.380 - 7.380
52wk Range 4.000 - 10.24
Shares Outstanding 21,331,314
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Under-$10 Biotech Stocks That Could Make You Rich
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis. 
Via InvestorPlace
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
These are the clinical-stage biotech stocks to buy, as they represent companies with an attractive product pipeline. 
Via InvestorPlace

Performance

YTD
+38.72%
+38.72%
1 Month
-8.66%
-8.66%
3 Month
-18.81%
-18.81%
6 Month
+42.75%
+42.75%
1 Year
+2.64%
+2.64%

More News

Read More
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
Via Newsfile
Actinium Presents Exciting Data On Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Via AB Newswire
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
Via FinancialNewsMedia
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
From FN Media Group LLC
Via GlobeNewswire
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
Via FinancialNewsMedia
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
Via Newsfile
Actinium Presents First Ever Data Demonstrating Statistically Significant Anti-Tumor Control and Potent Leukemic Cell Killing with Actimab-A in Combination with Leading Menin Inhibitors in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Via FinancialNewsMedia
Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
Via InvestorPlace
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
Via InvestorPlace
3 Cheap Biotech Stocks to Buy Now: May 2024
Via InvestorPlace
Exposures Product Safety
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
Via AB Newswire
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
Via AB Newswire
ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024
Via InvestorPlace
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Via Investor's Business Daily
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
Via AB Newswire
Topics Economy
Exposures Interest Rates
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
Via AB Newswire
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
Via InvestorPlace
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
Via AB Newswire
Actinium Pharmaceuticals (ATNM) Spearheading the Future of Oncology with Iomab-ACT’s Innovative Clinical Trial
Via AB Newswire
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.